Navigation Links
Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
Date:10/3/2007

ne of novel compounds targeting G protein-coupled receptors, an important class of validated drug targets, includes compounds being evaluated independently and with its partners, Merck & Co., Inc. and Ortho-McNeil Pharmaceutical, Inc.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's strategy, preclinical and internal and partnered clinical programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, Arena's planned clinical trials may not proceed at the time Arena expects or at all, the results of preclinical studies or clinical trials may not be predictive of future results, Arena's ability to partner lorcaserin, APD125, APD791 or other of its compounds or programs, the timing, success and cost of Arena's research, out-licensing endeavors and clinical trials, Arena's ability to obtain additional financing, Arena's ability to obtain and defend its patents, and the timing and receipt of payments and fees, if any, from Arena's collaborators. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
4. Wisconsin firms to present at Cleantech venture capital event
5. New Sonic Foundry search engine finds words, phrases in video presentations
6. Lone Wisconsin firm to present at InvestMidwest
7. Sonic Foundry creates search engine for 7,000 expert video presentations
8. InvestMidWest calls for business presentations
9. Wicab to present BrainPort at Boston conference
10. Three more Wisconsin firms to present at venture forum
11. Six Wisconsin firms to present at BIO Mid-America VentureForum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... 14 Vermillion, Inc. (Pink Sheets: ... William C. Wallen, Ph.D. Chief Scientific Officer, ... IDEXX Laboratories, will be joining its board ... plan. ,, "Bill brings more than ... diagnostics and biotechnology," said Gail Page, Vermillion ...
(Date:12/14/2009)... NATICK, Mass., Dec. 14 Boston Scientific Corporation ... of a public offering of $2 billion aggregate principal ... registration statement. The public offering consists of $850 ... million of 6.00 percent notes due January 2020 and ... Boston Scientific plans to use the net proceeds ...
(Date:12/14/2009)... of Brookfield Engineering’s Powder Flow Tester – helping Brookfield move ... footprint and more compact design. , ... ... US-based thermoforming company, has completed the delivery of Brookfield Engineering’s ... to a plastic enclosure with a smaller footprint and more ...
(Date:12/11/2009)... 2009 miRagen Therapeutics, Inc., a biopharmaceutical company ... microRNA-based therapeutics for cardiovascular and muscle disease, today ... (miR-206) plays a crucial role in the progression ... disease) and in neuromuscular synaptic regeneration in mice. ... issue of the journal Science , reveal ...
Breaking Biology Technology:Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors 2Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors 3Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors 4Boston Scientific Announces Completion of $2 Billion Senior Notes Offering 2Boston Scientific Announces Completion of $2 Billion Senior Notes Offering 3Thermofab Helps Brookfield Engineering Move To A Compact Custom Plastic Enclosure 2miRagen announces discovery of key microRNA implicated in Lou Gehrig's disease 2
... YORK, April 21 Crystal Research Associates, LLC announced ... (EIO(R)) on ACT Biotech, Inc. The full 56-page report ... Biotech, Inc. ("ACT Biotech" or "the Company") is a ... and commercialization of novel cancer therapeutics. Following a technology ...
... Vantia Therapeutics, a,company developing novel small molecule ... appointment of Rachel Morten as Head of,Regulatory Affairs. ... than 24 years experience in global regulatory affairs ... industries. Most,recently an independent regulatory affairs consultant, Rachel ...
... Esther Chang describes the most recent developments in ... nanoparticle method designed to restore normal gene function ... April 21 at an American Association of Anatomists ... New Orleans. , Dr. Chang, a molecular oncologist, ...
Other Biology Technology:Crystal Research Associates, LLC Issues an Executive Informational Overview(R) (EIO(R)) on ACT Biotech, Inc. 2Crystal Research Associates, LLC Issues an Executive Informational Overview(R) (EIO(R)) on ACT Biotech, Inc. 3Vantia Therapeutics Appoints Rachel Morten as Head of Regulatory Affairs 2Vantia Therapeutics Appoints Rachel Morten as Head of Regulatory Affairs 3Vantia Therapeutics Appoints Rachel Morten as Head of Regulatory Affairs 4Fat droplet nanoparticle delivers tumor suppressor gene to tumor and metastatic cells 2
(Date:12/15/2009)... is available in German . , Leipzig: ... predicting the future distribution of mammals. This is the ... 140 indigenous European mammals. The researchers analysed data on ... as the phylogenetic information of the species. Judging by ... related species, mammals seem to adapt fast to changing ...
(Date:12/14/2009)... researchers are part of an international team that has ... to revise the history of North America,s woolly mammoths ... A Earth and Atmospheric Sciences professor Duane Froese and ... radiocarbon dating of bones and teeth. That analysis concluded ... North America (the ,megafauna,) disappeared about 13,000 years ago. ...
(Date:12/14/2009)... Biomedical Engineering Society (BMES) have founded a new journal ... CVET is a forum for research ... The first issue of the new quarterly journal ... BMES publications at Springer, Annals of Biomedical Engineering ... Cardiovascular Engineering and Technology will present a ...
Breaking Biology News(10 mins):Species distribution models are of only limited value for predicting future mammal distributions 2Biomedical Engineering Society's new journal to be published by Springer 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 15062 1Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 15062 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 15062 3Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 15062 4Cardium Files FDA 510 28k 29 Application for U S Marketing Clearance of ExcellagenXL 28TM 29 Topical Gel and ExcellagenFX 28TM 29 Flowable Collagen P 6732 1Cardium Files FDA 510 28k 29 Application for U S Marketing Clearance of ExcellagenXL 28TM 29 Topical Gel and ExcellagenFX 28TM 29 Flowable Collagen P 6732 2Cardium Files FDA 510 28k 29 Application for U S Marketing Clearance of ExcellagenXL 28TM 29 Topical Gel and ExcellagenFX 28TM 29 Flowable Collagen P 6732 3Cardium Files FDA 510 28k 29 Application for U S Marketing Clearance of ExcellagenXL 28TM 29 Topical Gel and ExcellagenFX 28TM 29 Flowable Collagen P 6732 4Cardium Files FDA 510 28k 29 Application for U S Marketing Clearance of ExcellagenXL 28TM 29 Topical Gel and ExcellagenFX 28TM 29 Flowable Collagen P 6732 5Jazz Pharmaceuticals Appoints Kathryn Falberg as Chief Financial Officer 6728 1
... single compound to increase the lifespan of obese mice, ... the changes in gene expression patterns found in mice ... diabetes, heart disease, and other significant diseases related to ... School and the National Institute on Aging, is the ...
... be perpetuated between generations by changes in the brain ... Chicago shows. , A research team found that when ... mild abuse in their first month of life, their brains ... the brain. Low levels of serotonin are associated with anxiety ...
... and threatening human well-being, according to a report published ... Science published by AAAS, the nonprofit science society. ... this trend has recently been accelerating," said lead author ... the consequences. For example, if the long-term trend continues, ...
Other Biology News:Single molecule extends fat mice lives by reversing gene pathways associated with disease in obese 2Single molecule extends fat mice lives by reversing gene pathways associated with disease in obese 3Single molecule extends fat mice lives by reversing gene pathways associated with disease in obese 4Single molecule extends fat mice lives by reversing gene pathways associated with disease in obese 5Low levels of neurotransmitter serotonin may perpetuate child abuse across generations 2Low levels of neurotransmitter serotonin may perpetuate child abuse across generations 3By 2048 all current fish, seafood species projected to collapse 2By 2048 all current fish, seafood species projected to collapse 3
mitochondrial proteins (human heart) for 2-D gel electrophoresis *5 mg/mL*...
... undoubtedly the most complete and professional software ... layers and subsets makes it is possible ... data outputs, for example Cy3 and Cy5, ... as different subsets of genes and/or arrays. ...
...
...
Biology Products: